ArticleBlood cancer journal2024
Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND).
Abstract readComparative StudyLetter
In one paragraph
Article in Blood cancer journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 1 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it.
- American Society of Hematology 2025 guidelines for treating newly diagnosed acute myeloid leukemia in older adults.Blood advances · 2026Guideline
- CPX-351 selectively benefits patients with AML and myelodysplasia-related mutations in the pivotal randomized trial.Blood advances · 2026Trial
- Limited Survival Benefit and High Healthcare Utilization With AML-Directed Therapy in Older Patients With TP53 -Mutated Acute Myeloid Leukemia.American journal of hematology · 2026Article
- Choice of hypomethylating agent for newly diagnosed TP53-mutant acute myeloid Leukemia: a COMMAND registry study.Leukemia · 2026Article
- Newly diagnosed acute myeloid leukemia in Fit patients: 2026 treatment algorithms.Blood cancer journal · 2026Review
- Hypomethylating agents plus venetoclaxHaematologica · 2026Article
- Response to Comment on: "Clinical interrogation ofHaematologica · 2026Article
- Clinical outcomes of venetoclax combined with hypomethylating agentsHaematologica · 2026Article
- Isolated Neutropenia as a Sentinel of High-Risk Clonal Evolution: Acute Myeloid Leukemia With Myelodysplasia-Related Changes HarboringJournal of medical cases · 2026Article
- Review
- How to Read a Next-Generation Sequencing Report for AML and MDS? What Hematologists Need to Know.Journal of clinical medicine · 2025Review
- Outcomes of older patients with TP53-mutated myeloid neoplasms.Blood cancer journal · 2025Article
- Newly diagnosed acute myeloid leukemia in unfit patients: 2026 treatment algorithms.Blood cancer journal · 2025Review
- Article
- Long-term follow-up and combined Phase 2 results of eprenetapopt and azacitidine in patients withHemaSphere · 2025Article
- TP53-Mutated Acute Myeloid Leukemia: Unanswered Questions.Hematological oncology · 2025Review
- Barriers to allogeneic stem cell transplantation in responding patients with TP53-mutated acute myeloid leukemia.Bone marrow transplantation · 2025Article
- TP53 -Mutated Myeloid Neoplasms: 2024 Update on Diagnosis, Risk-Stratification, and Management.American journal of hematology · 2025Review
- Somatic co-alteration signatures are prognostic in high-grade TP53-mutated myeloid neoplasms.British journal of haematology · 2025Article
- T-cell immune cluster analysis using CyTOF identifies unique subgroups of patients with acute myeloid leukemia.Blood advances · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Talha BadarDivision of Hematology-Oncology, Mayo Clinic, Jacksonville, FL, USA. badar.talha@mayo.edu.ORCID 0000-0003-1548-918X
Ahmad NanaaDivision of Hematology-Oncology, Mayo Clinic, Jacksonville, FL, USA.ORCID 0000-0001-5247-5065
Ehab AtallahDivision of Hematology and Medical Oncology, Medical College of Wisconsin, Milwaukee, WI, USA.
Rory M ShallisSection of Hematology, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA.
Sacchi de Camargo Correia GuilhermeDepartment of Internal Medicine, Mount Sinai Health System, New York, USA.
Aaron D GoldbergDivision of Hematologic Malignancies, Department of Medicine Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Antoine N SalibaDivision of Hematology, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0001-5134-7336
Anand PatelSection of Hematology and Oncology, Department of Medicine, University of Chicago, Chicago, IL, USA.ORCID 0000-0002-0296-8686
Jan P BewersdorfDivision of Hematologic Malignancies, Department of Medicine Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0003-3352-0902
Adam S DuVallDivision of Hematology and Oncology, Georgia Cancer Center, Augusta, GA, USA.
Danielle BradshawDivision of Hematology and Oncology, Georgia Cancer Center, Augusta, GA, USA.
Yasmin AbazaRobert H. Lurie Comprehensive Cancer Center, Northwestern Hospital, Chicago, IL, USA.ORCID 0000-0002-9156-7912
Guru Subramanian Guru MurthyDivision of Hematology and Medical Oncology, Medical College of Wisconsin, Milwaukee, WI, USA.
Neil PalmisianoDivision of Hematology and Oncology, Jefferson University Hospital, Philadelphia, PA, USA.
Amer M ZeidanSection of Hematology, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA.
Vamsi KotaDivision of Hematology and Oncology, Georgia Cancer Center, Augusta, GA, USA.ORCID 0000-0002-5290-9289
Mark R LitzowDivision of Hematology, Mayo Clinic, Rochester, MN, USA.
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4MYale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9MYale Pathology Tissue Services Shared ResourceP30CA016359 · NCI · YALE UNIVERSITY · PI MEGAN C KING · 1985 to 2026
$85.0MTargeting Drug-Resistant Castration Resistant Prostate Cancer via LIMK2R01CA237660 · NCI · PURDUE UNIVERSITY · PI RATLIFF, TIMOTHY L. · 2020 to 2024
$1.2MNCATS NIH HHS UL1 TR001863NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA016359NCI NIH HHS R01 CA237660
Abstract
PubMed holds no abstract for this paper.
Indexed as
Leukemia, Myeloid, AcuteAntineoplastic Combined Chemotherapy ProtocolsBridged Bicyclo Compounds, HeterocyclicHumansSulfonamidesTumor Suppressor Protein p53Bridged Bicyclo Compounds, HeterocyclicSulfonamidesTP53 protein, humanTumor Suppressor Protein p53venetoclax
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.